The Big Picture
Imagine needing brain surgery. Today, this often means multiple operations, a fully opened skull, and weeks in the hospital. NeuroOne (NMTC) is changing this with new technology that lets doctors treat patients through a tiny hole, in a single hospital visit, right at their bedside.
What Makes NeuroOne Special?
They make super-thin electrodes (like tiny wires) that doctors use in brain surgery
Their devices are 90% thinner than what's used today
Most importantly, their newest product (OneRF) can both find and treat problem areas in the brain using the same device
Strong Partnership
Zimmer Biomet, a $25 billion medical device company, sells NeuroOne's products. They just expanded their partnership and paid NeuroOne $3 million upfront for rights to sell the new OneRF system. This is huge validation from an industry leader.
The Market Opportunity
About 50,000 Americans each year need this kind of treatment for epilepsy
Current methods are so invasive that only 5,000 actually get surgery
NeuroOne's simpler approach could help many more patients say yes to treatment
Each procedure brings in about $5,000 in revenue
Beyond Epilepsy
NeuroOne's technology could also help with:
Chronic pain treatment ($2.3 billion market)
Delivering drugs directly to the brain ($7 billion market by 2025)
Parkinson's disease treatment ($3.4 billion market by 2033)
The Numbers
Current stock price: Around $1
Market value: About $25 million
Revenue growing 100% year over year
Need about $5 million more to reach breakeven
Recently raised $2.65 million and got $3 million from Zimmer
Why It's Interesting Now
Continue Reading
Click To Read More
